{"disease":{"id":"relapsed-refractory-b-precursor-acute-lymphoblastic-leukemia","name":"relapsed refractory b precursor acute lymphoblastic leukemia"},"drugs":{"marketed":[{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02013167","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":405,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02614066","title":"A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT07134088","title":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02625480","title":"Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false},{"nct_id":"NCT02412306","title":"Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06054113","title":"Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02187354","title":"Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Amgen","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}